Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results